Checkpoint kinase‑1 inhibition and etoposide exhibit a strong synergistic anticancer effect on chronic myeloid leukemia cell line K562 by impairing homologous recombination DNA damage repair

Zhuoyi Fan, Huacheng Luo, Jie Zhou, Fangce Wang, Wenjun Zhang, Jian Wang, Shuo Li, Qian Lai, Yueshuang Xu, Guangming Wang, Aibin Liang, Jun XuOncology 2020 · DOI

Abstract

Chemotherapeutic resistance remains a significant hurdle in treating leukemia, often driven by the cancer cell's enhanced DNA damage response (DDR). This study investigates the role of Checkpoint kinase 1 (CHK1) in the chronic myeloid leukemia (CML) cell line K562. We demonstrate that inhibiting CHK1—either through genetic silencing or the small molecule inhibitor CCT245737—synergizes with etoposide (VP16) to induce apoptosis. This effect is achieved by overriding the G2/M checkpoint and impairing homologous recombination (HR) repair through the downregulation of BRCA1 and Rad51.

The Challenge: Overcoming Resistance in CML

While tyrosine kinase inhibitors (TKIs) like imatinib have transformed CML treatment, resistance often develops. A key mechanism of this resistance is the upregulation of DNA repair pathways, which allow cancer cells to survive the genomic stress induced by chemotherapy. CHK1 is a master regulator of the G2/M checkpoint, providing cells the time needed to repair double-strand breaks.

Baseline CHK1 expression levels in CML cell lines KCL22 and K562.

As shown in the figure above, the K562 cell line exhibits significantly higher baseline levels of CHK1 mRNA and protein compared to KCL22, making it an ideal model for studying CHK1-mediated resistance.

Methods and Validation

To explore the therapeutic potential of CHK1, researchers used both genetic and pharmacological approaches. Genetic silencing was achieved using short hairpin RNA (shRNA) to knockdown CHK1 expression in K562 cells.

Validation of shRNA-mediated CHK1 mRNA knockdown.

The efficacy of this knockdown (shKD) was confirmed via quantitative PCR, showing a near-total reduction in CHK1 mRNA levels compared to vector and non-coding (shNC) controls. Additionally, the study utilized CCT245737, a selective CHK1 inhibitor, to test pharmacological synergy with etoposide.

Key Insights: Breaking the Repair Machinery

The study revealed two primary mechanisms for the observed synergy:

  1. Checkpoint Override: CHK1 inhibition prevents cells from arresting in the G2/M phase. Instead of pausing to repair DNA damage caused by etoposide, cells are forced into a premature and lethal mitosis.
  2. HR Repair Impairment: Crucially, CHK1 inhibition leads to the downregulation of BRCA1 and Rad51, the essential components of the homologous recombination (HR) repair pathway. Without these "repair crews," the DNA damage remains unrepaired.

Results and Synergy

Using the Chou-Talalay method, the researchers calculated a Combination Index (CI) of 0.35 in K562 cells, indicating strong synergy. This effect was even more pronounced in imatinib-pretreated cells (CI = 0.15), suggesting that this combination could be particularly effective in TKI-resistant cases. Comet assays further confirmed a massive accumulation of DNA breaks in the combination group compared to monotherapies.

Conclusion

These findings highlight CHK1 as a potent therapeutic target in CML. By combining CHK1 inhibitors like CCT245737 with standard chemotherapy, it is possible to bypass the cell's repair mechanisms and overcome resistance. Future studies in animal models are warranted to further evaluate the clinical potential of this synergistic strategy.

Summary updated

Abstract

Leukemia, a malignant hematological disease, has poor therapeutic outcomes due to chemotherapeutic resistance. Increasing evidence has confirmed that the elevated capacity for DNA damage repair in cancer cells is a major mechanism of acquired chemotherapeutic resistance. Thus, combining chemotherapy with inhibitors of DNA damage repair pathways is potentially an ideal strategy for treating leukemia. Checkpoint kinase 1 (CHK1) is an important component of the DNA damage response (DDR) and is involved in the G2/M DNA damage checkpoint. In the present study, we demonstrated that shRNA‑mediated CHK1 silencing suppressed cell proliferation and enhanced the cytotoxic effects of etoposide (VP16) in the chronic myeloid leukemia (CML) cell line K562 through the results of CCK‑8, and comet assay. The results demonstrated that shRNA‑induced CHK1 silencing can override G2/M arrest and impair homologous recombination (HR) repair by reducing breast cancer susceptibility gene 1 (BRCA1) expression. Cells had no time, and thus limited ability, to repair the damage and were thus more sensitive to chemotherapy after CHK1 downregulation. Second, we tested the therapeutic effect of VP16 combined with CCT245737, an orally bioavailable CHK1 inhibitor, and observed strong synergistic anticancer effects in K562 cells. Moreover, we discovered that CCT245737 significantly prevented the G2/M arrest caused by acute exposure to VP16. Interestingly, CCT245737 inhibited both BRCA1 and Rad51, the most important component of the HR repair pathway. In conclusion, these results revealed that CHK1 is potentially an ideal therapeutic target for the treatment of CML and that CCT245737 should be considered a candidate drug.
BibTeX
@inproceedings{fan2020checkpoint,
  author = {Zhuoyi Fan and Huacheng Luo and Jie Zhou and Fangce Wang and Wenjun Zhang and Jian Wang and Shuo Li and Qian Lai and Yueshuang Xu and Guangming Wang and Aibin Liang and Jun Xu},
  title = {{Checkpoint kinase‑1 inhibition and etoposide exhibit a strong synergistic anticancer effect on chronic myeloid leukemia cell line K562 by impairing homologous recombination DNA damage repair}},
  booktitle = {Oncology},
  year = {2020},
  doi = {10.3892/or.2020.7757},
}
Figure